Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer | SpringerLink
Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center | Journal of the Egyptian National Cancer Institute | Full Text
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer | SpringerLink
Kaplan-Meier plot of median Os (interim analysis) (n=90).... | Download Scientific Diagram
The median OS of the patients. OS, overall survival. | Download Scientific Diagram
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Time-dependent endpoints as predictors of overall survival in multiple myeloma | BMC Cancer | Full Text
Overall survival (OS) analyses. Case numbers, median OS and P-values... | Download Scientific Diagram
The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion | Scientific Reports
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Efficacy Data | Xofigo® (Radium Ra 223 Dichloride)
Overall survival. Median OS was 13 months (95%Cl 9–16). | Download Scientific Diagram
KarMMa Survival Rates | ABECMA® (idecabtagene vicleucel)
Kaplan-Meier plots for survivals. In Figure 2A, a median OS of 9.1... | Download Scientific Diagram
Time-dependent endpoints as predictors of overall survival in multiple myeloma | BMC Cancer | Full Text
Median OS vs Hazard Ratio | Stivarga Global Website
The median OS of the patients. OS, overall survival. | Download Scientific Diagram
Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Efficacy I PLUVICTO
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Median OS vs Hazard Ratio | Stivarga Global Website
Overall survival (OS) of all patients. The median OS is 26 months (95 %... | Download Scientific Diagram
